Scarica l'app Stockscreener
125.00
3.53%
-4.58
Dopo l'orario di chiusura:
125.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$129.58
Aprire:
$129.91
Volume 24 ore:
495.65K
Relative Volume:
0.90
Capitalizzazione di mercato:
$6.24B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-19.14
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
+2.02%
1M Prestazione:
+9.55%
6M Prestazione:
+19.65%
1 anno Prestazione:
+38.94%
Intervallo 1D:
$124.02
$130.81
Intervallo di 1 settimana:
$119.20
$130.81
Portata 52W:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
125.00 | 6.16B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Is Axsome Therapeutics Inc a good long term investmentEarnings Volatility Patterns & Grow Generational Wealth With Ease - earlytimes.in
Is Axsome Therapeutics Inc. stock gaining market shareTrade Risk Assessment & Weekly Stock Performance Updates - newser.com
(AXSM) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
How Axsome Therapeutics Inc. stock performs in rate cut cyclesTrade Risk Report & Safe Entry Point Identification - newser.com
Will Axsome Therapeutics Inc. (19X) stock outperform global peersJuly 2025 PreEarnings & Long Hold Capital Preservation Plans - newser.com
How Axsome Therapeutics Inc. stock compares to market leadersBond Market & Long-Term Safe Investment Plans - newser.com
Q2 EPS Forecast for Axsome Therapeutics Lifted by Analyst - MarketBeat
Can Axsome Therapeutics Inc. stock withstand economic slowdownRecession Risk & Real-Time Stock Price Movement Reports - newser.com
Top chart patterns to watch in Axsome Therapeutics Inc.2025 Stock Rankings & Real-Time Volume Triggers - newser.com
KLP Kapitalforvaltning AS Raises Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
What candlestick patterns are forming on Axsome Therapeutics Inc.Analyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
Axsome Therapeutics Inc. stock volume spike explainedShare Buyback & AI Powered Market Entry Ideas - newser.com
Will Axsome Therapeutics Inc. (19X) stock deliver stable dividendsMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
Axsome Therapeutics Inc. stock trend forecast2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Tools to assess Axsome Therapeutics Inc.’s risk profileQuarterly Risk Review & Long-Term Capital Growth Strategies - newser.com
Axsome Therapeutics (AXSM) Stock Analysis: Unpacking A Potential 45% Upside In Biotech - DirectorsTalk Interviews
Axsome Therapeutics, Inc. $AXSM Shares Sold by Blair William & Co. IL - MarketBeat
What is William Blair's Estimate for AXSM FY2026 Earnings? - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
IFP Advisors Inc Sells 4,096 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 EPS Estimate for Axsome Therapeutics Reduced by Analyst - MarketBeat
Can trapped investors hope for a rebound in Axsome Therapeutics Inc.Gap Up & Verified Stock Trade Ideas - newser.com
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,590,330.30 in Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,518,062.16 in Stock - MarketBeat
Herriot Tabuteau Sells 19,220 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Axsome Therapeutics (AXSM): Exploring Valuation After Recent Share Price Stability - Yahoo Finance
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community - The Manila Times
Real time social sentiment graph for Axsome Therapeutics Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
1 in 5 U.S. adults affected — Axsome Recognizes Mental Illness Awareness Week and shares NAMI resources - Stock Titan
Axsome therapeutics CEO sells $5.4m in shares By Investing.com - Investing.com Canada
Axsome therapeutics CEO sells $5.4m in shares - Investing.com
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Axsome Therapeutics Schedule Third Quarter 2025 Financial Results Announcement and Conference Call - Quiver Quantitative
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - The Manila Times
Knights of Columbus Asset Advisors LLC Grows Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast - Stock Titan
Is Axsome Therapeutics Inc 19X a good long term investmentVolatility Adjusted Trading & Free Trading Psychology Sessions - earlytimes.in
J. Safra Sarasin Holding AG Purchases 9,998 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Meet Herriot Tabuteau, The Haitian-Born Doctor Whose Brain Disorder Medications Turned Into A $6 Billion Empire - Black Enterprise
What is B. Riley's Estimate for AXSM Q3 Earnings? - MarketBeat
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation - Yahoo Finance
Migraine Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories - Barchart.com
Axsome Therapeutics (NASDAQ:AXSM) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Option Exercise |
8.02 |
13,390 |
107,388 |
20,619 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Option Exercise |
8.02 |
12,774 |
102,447 |
20,003 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Sale |
120.17 |
19,220 |
2,309,667 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Sale |
118.77 |
13,390 |
1,590,330 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Sale |
118.84 |
12,774 |
1,518,062 |
7,229 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):